Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

Sun,Wei; Hu,Qihong; Liu,Zhi; Zhang,Qing; Wang,Jian

doi:10.3892/ol.2024.14677

Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma

Authors:
- Wei Sun
- Qihong Hu
- Zhi Liu
- Qing Zhang
- Jian Wang
View Affiliations

Affiliations: Department of Thyroid and Breast Surgery, Ma'anshan People's Hospital, Ma'anshan, Anhui 243000, P.R. China, Department of Pathology, Ma'anshan People's Hospital, Ma'anshan, Anhui 243000, P.R. China
Published online on: September 10, 2024 https://doi.org/10.3892/ol.2024.14677
Article Number: 544
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Papillary thyroid carcinoma (PTC) exhibits a trend of multifocal growth. However, the clonal origin of multiple cancer foci in the thyroid gland remains an issue of ongoing debate. In order to investigate the clonal origin and biological behavior differences of multifocal PTC (MPTC) from a unique perspective, a combination of dual gene and dual protein detection methods was used. The present study included 52 patients with MPTC. Immunohistochemical staining was used to assess the expression of v‑raf murine sarcoma viral oncogene homolog B1 (BRAF) and telomerase reverse transcriptase (TERT) proteins, while quantitative PCR and Sanger sequencing were used to identify BRAF and TERT gene mutations. Based on the results, MPTC cases were classified into two clonal origins, namely intraglandular metastatic (71.2%) and independent multicentric origin (28.8%). BRAF protein expression and BRAF gene mutation were significantly higher in the intraglandular metastasis group than in the multicentric cancer group. However, no significant differences in TERT protein expression and TERT gene mutation were observed between the two groups. Sex, central lymph node metastasis rate, Hashimoto's thyroiditis and tumor distribution laterality were not found to differ significantly between the two groups. However, significant differences were detected in age at initial diagnosis, lateral cervical lymph node metastasis rate, tumor capsule invasion rate and maximum tumor diameter. The study found that MPTC predominantly occurs due to intraglandular metastasis, which is associated with stronger tumor invasiveness than cancer foci with multiple independent origins, as it is more likely to exhibit pathogenic gene mutations and abnormal protein expression, cervical lymph node metastasis and capsule invasion. Therefore, it is recommended that the surgical approaches and follow‑up strategies for intraglandular metastatic MPTC should be aggressive and individualized.

View Figures

View References

1	Choi WR, Roh JL, Gong G, Cho KJ, Choi SH, Nam SY and Kim SY: Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence. Oral Oncol. 94:106–110. 2019. View Article : Google Scholar : PubMed/NCBI
2	Zhang JW, Fei MJ, Hou YQ, Tang ZY, Zhan WW and Zhou JQ: Long-term follow-up ultrasonography surveillance in a large cohort of patients with papillary thyroid carcinoma. Endocrine. 77:297–304. 2022. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, Zeng HM, Wei WW and He J: Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 46:221–231. 2024.(In Chinese). PubMed/NCBI
5	Li M, Zheng R, Dal Maso L, Zhang S, Wei W and Vaccarella S: Mapping overdiagnosis of thyroid cancer in China. Lancet Diabetes Endocrinol. 9:330–332. 2021. View Article : Google Scholar : PubMed/NCBI
6	Li M, Dal Maso L and Vaccarella S: Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 8:468–470. 2020. View Article : Google Scholar : PubMed/NCBI
7	Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M and Dal Maso L: Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 375:614–617. 2016. View Article : Google Scholar : PubMed/NCBI
8	Dal Maso L, Panato C, Franceschi S, Serraino D, Buzzoni C, Busco S, Ferretti S, Torrisi A, Falcini F, Zorzi M, et al: The impact of overdiagnosis on thyroid cancer epidemic in Italy, 1998–2012. Eur J Cancer. 94:6–15. 2018. View Article : Google Scholar : PubMed/NCBI
9	Roman BR, Morris LG and Davies L: The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes. 24:332–336. 2017. View Article : Google Scholar : PubMed/NCBI
10	Kiriakopoulos A, Petralias A and Linos D: Multifocal versus solitary papillary thyroid carcinoma. World J Surg. 40:2139–2143. 2016. View Article : Google Scholar : PubMed/NCBI
11	Cui L, Feng D, Zhu C, Li Q, Li W and Liu B: Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis. Laryngoscope Investig Otolaryngol. 7:1224–1234. 2022. View Article : Google Scholar : PubMed/NCBI
12	Park SY, Park YJ, Lee YJ, Lee HS, Choi SH, Choe G, Jang HC, Park SH, Park DJ and Cho BY: Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: Evidence of independent clonal origin in distinct tumor foci. Cancer. 107:1831–1838. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bansal M, Gandhi M, Ferris RL, Nikiforova MN, Yip L, Carty SE and Nikiforov YE: Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma. Am J Surg Pathol. 37:1586–1591. 2013. View Article : Google Scholar : PubMed/NCBI
14	McCarthy RP, Wang M, Jones TD, Strate RW and Cheng L: Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res. 12:2414–2418. 2006. View Article : Google Scholar : PubMed/NCBI
15	Kuhn E, Teller L, Piana S, Rosai J and Merino MJ: Different clonal origin of bilateral papillary thyroid carcinoma, with a review of the literature. Endocr Pathol. 23:101–107. 2012. View Article : Google Scholar : PubMed/NCBI
16	Nikiforova MN and Nikiforov YE: Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar : PubMed/NCBI
17	Liu R and Xing M: TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 23:R143–R155. 2016. View Article : Google Scholar : PubMed/NCBI
18	Czarniecka A, Oczko-Wojciechowska M and Barczyński M: BRAF V600E mutation in prognostication of papillary thyroid cancer (PTC) recurrence. Gland Surg. 5:495–505. 2016. View Article : Google Scholar : PubMed/NCBI
19	Rashid FA, Munkhdelger J, Fukuoka J and Bychkov A: Prevalence of BRAF^V600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg. 9:1878–1900. 2020. View Article : Google Scholar : PubMed/NCBI
20	Calado RT: Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program. 1:338–343. 2009. View Article : Google Scholar : PubMed/NCBI
21	Vuong HG, Altibi AMA, Duong UNP and Hassell L: Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-a meta-analysis. Clin Endocrinol (Oxf). 87:411–417. 2017. View Article : Google Scholar : PubMed/NCBI
22	Tam AA, Özdemir D, Çuhacı N, Başer H, Aydın C, Yazgan AK, Ersoy R and Çakır B: Association of multifocality, tumor number, and total tumor diameter with clinicopathological features in papillary thyroid cancer. Endocrine. 53:774–783. 2016. View Article : Google Scholar : PubMed/NCBI
23	Feng JW, Wu WX, Hu J, Hong LZ, Qin AC, Jiang Y and Ye J: Influence of tumor number on clinicopathologic features and outcomes of patients with papillary thyroid carcinoma. Am J Clin Pathol. 154:848–858. 2020. View Article : Google Scholar : PubMed/NCBI
24	Qu N, Zhang L, Ji QH, Zhu YX, Wang ZY, Shen Q, Wang Y and Li DS: Number of tumor foci predicts prognosis in papillary thyroid cancer. BMC Cancer. 14:9142014. View Article : Google Scholar : PubMed/NCBI
25	Kim H, Kwon H and Moon BI: Association of multifocality with prognosis of papillary thyroid carcinoma: A systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 147:847–854. 2021. View Article : Google Scholar : PubMed/NCBI
26	Feng JW, Qu Z, Qin AC, Pan H, Ye J and Jiang Y: Significance of multifocality in papillary thyroid carcinoma. Eur J Surg Oncol. 46:1820–1828. 2020. View Article : Google Scholar : PubMed/NCBI
27	Lin JD, Chao TC, Hsueh C and Kuo SF: High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol. 16:2609–2616. 2009. View Article : Google Scholar : PubMed/NCBI
28	Woo J, Kim H and Kwon H: Impact of multifocality on the recurrence of papillary thyroid carcinoma. J Clin Med. 10:51442021. View Article : Google Scholar : PubMed/NCBI
29	Muzza M: The clonal origin of multifocal papillary thyroid cancer: Intrathyroidal spread or independent tumors? Minerva Endocrinol (Torino). 46:35–44. 2021.PubMed/NCBI
30	Chen D, Qi W, Xie S, Feng L, Wang J, Wang L and Guan H: Investigation of the clonal origin of multifocal papillary thyroid carcinoma according to the X-chromosome inactivation pattern. Oncol Lett. 17:4695–4700. 2019.PubMed/NCBI
31	Jovanovic L, Delahunt B, McIver B, Eberhardt NL and Grebe SK: Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol. 215:145–154. 2008. View Article : Google Scholar : PubMed/NCBI
32	Nakazawa T, Kondo T, Tahara I, Kasai K, Inoue T, Oishi N, Mochizuki K, Kubota T and Katoh R: Multicentric occurrence of multiple papillary thyroid carcinomas-HUMARA and BRAF mutation analysis. Cancer Med. 4:1272–1280. 2015. View Article : Google Scholar : PubMed/NCBI
33	Lin X, Finkelstein SD, Zhu B and Silverman JF: Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol. 41:195–203. 2008. View Article : Google Scholar : PubMed/NCBI
34	Lu Z, Sheng J, Zhang Y, Deng J, Li Y, Lu A, Zhang J, Yu H, Zhang M, Xiong Z, et al: Clonality analysis of multifocal papillary thyroid carcinoma by using genetic profiles. J Pathol. 239:72–83. 2016. View Article : Google Scholar : PubMed/NCBI
35	Shattuck TM, Westra WH, Ladenson PW and Arnold A: Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 352:2406–2412. 2005. View Article : Google Scholar : PubMed/NCBI
36	Trimboli P, Piccardo A, Signore A, Valabrega S, Barnabei A, Santolamazza G, Di Paolo A, Stati V, Chiefari A, Vottari S, et al: Patient age is an independent risk factor of relapse of differentiated thyroid carcinoma and improves the performance of the American Thyroid Association stratification system. Thyroid. 30:713–719. 2020. View Article : Google Scholar : PubMed/NCBI
37	Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, et al: Defining a valid age cutoff in staging of welldifferentiated thyroid cancer. Ann Surg Oncol. 23:410–415. 2016. View Article : Google Scholar : PubMed/NCBI
38	Mazzaferri EL and Kloos RT: Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 86:1447–1463. 2001. View Article : Google Scholar : PubMed/NCBI
39	Voutilainen PE, Siironen P, Franssila KO, Sivula A, Haapiainen RK and Haglund CH: AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res. 23:4283–4288. 2003.PubMed/NCBI
40	Sun Y, Dai W, Liang Y and Xia N: Impact of age on the prognosis of papillary thyroid carcinoma. Arch Iran Med. 23:169–174. 2020.PubMed/NCBI
41	Ito Y, Kudo T, Kobayashi K, Miya A, Ichihara K and Miyauchi A: Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: Analysis of 5,768 patients with average 10-year follow-up. World J Surg. 36:1274–1278. 2012. View Article : Google Scholar : PubMed/NCBI
42	Soylu L, Aydin OU, Ozbas S, Bilezikci B, Ilgan S, Gursoy A and Kocak S: The impact of the multifocality and subtypes of papillary thyroid carcinoma on central compartment lymph node metastasis. Eur Rev Med Pharmacol Sci. 20:3972–3979. 2016.PubMed/NCBI
43	Genpeng L, Jianyong L, Jiaying Y, Ke J, Zhihui L, Rixiang G, Lihan Z and Jingqiang Z: Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer. Medicine (Baltimore). 97:e96192018. View Article : Google Scholar : PubMed/NCBI
44	Kim HJ, Sohn SY, Jang HW, Kim SW and Chung JH: Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg. 37:376–384. 2013. View Article : Google Scholar : PubMed/NCBI
45	Pancer J, Mitmaker E, Ajise O, Tabah R and How J: A thyroid gland with over 30 foci of papillary thyroid carcinoma with activating BRAF V600E mutation. Endocrinol Diabetes Metab Case Rep. 19:19–0006. 2019.PubMed/NCBI
46	Choi Y, Park KJ, Ryu S, Kim DH, Yun J, Kang DK and Chun M: Papillary thyroid carcinoma involving cervical neck lymph nodes: Correlations with lymphangiogenesis and ultrasound features. Endocr J. 59:941–948. 2012. View Article : Google Scholar : PubMed/NCBI
47	Dong S, Xie XJ, Xia Q and Wu YJ: Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis. Am J Cancer Res. 9:1786–1795. 2019.PubMed/NCBI
48	Zhao J and Luo Z: Discovery of Raf family is a milestone in deciphering the Ras-mediated intracellular signaling pathway. Int J Mol Sci. 23:51582022. View Article : Google Scholar : PubMed/NCBI
49	Russo M, Malandrino P, Nicolosi ML, Manusia M, Marturano I, Trovato MA, Pellegriti G, Frasca F and Vigneri R: The BRAF(V600E) mutation influences the short-and medium-term outcomes of classic papillary thyroid cancer but is not an independent predictor of unfavorable outcome. Thyroid. 24:1267–1274. 2014. View Article : Google Scholar : PubMed/NCBI
50	Jing C, Cao H, Ma R, Wu J and Wang Z: Association between mutation profiles and clinicopathological features in Chinese patients with thyroid cancer. Precision Medical Sciences. 10:113–117. 2021. View Article : Google Scholar
51	Yu P, Qu N, Zhu R, Hu J, Han P, Wu J, Tan L, Gan H, He C, Fang C, et al: TERT accelerates BRAF mutant-induced thyroid cancer dedifferentiation and progression by regulating ribosome biogenesis. Science Adv. 9:eadg71252023. View Article : Google Scholar : PubMed/NCBI